13694-84-3 Usage
General Description
(S)-3-Tosyltetrahydrofuran is a chemical compound with the molecular formula C11H16O3S. It is a tosylated derivative of tetrahydrofuran, which is a saturated cyclic ether commonly used as a solvent in chemical reactions. The tosyl group is a functional group containing a sulfonate ester, which imparts certain chemical properties to the compound. This chemical is often used as an intermediate in organic synthesis processes, and it can act as a precursor for the synthesis of various organic compounds. Additionally, it is known for its potential application in medicinal chemistry and drug development, with some studies exploring its pharmacological activities. Overall, (S)-3-Tosyltetrahydrofuran is a versatile compound with various industrial and pharmaceutical uses.
Check Digit Verification of cas no
The CAS Registry Mumber 13694-84-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,6,9 and 4 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 13694-84:
(7*1)+(6*3)+(5*6)+(4*9)+(3*4)+(2*8)+(1*4)=123
123 % 10 = 3
So 13694-84-3 is a valid CAS Registry Number.
13694-84-3Relevant articles and documents
BAX INHIBITORS AND USES THEREOF
-
Paragraph 00469; 00470, (2021/01/23)
A compound having formula (I) or (II) for use inhibiting Bax mediated cell death and/or apoptosis.
PIKFYVE KINASE INHIBITORS
-
Page/Page column 249, (2021/08/20)
The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF
-
Paragraph 0401; 1600-1602, (2020/01/08)
Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
